FAKTOR-OPTIONSSCHEIN - BIOTEST VZ | Market Closed - Börse Stuttgart 12:22:50 2024-05-24 EDT | ||
| 10.04 EUR | -2.24% |
|
| Current month | -10.99% | ||
| 1 month | -8.98% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOTEST AG
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 10.04 | -2.24% |
| 24-05-23 | 10.27 | -0.39% |
| 24-05-22 | 10.31 | +0.49% |
| 24-05-21 | 10.26 | +0.20% |
| 24-05-20 | 10.24 | +0.59% |
Delayed Quote Börse Stuttgart
Last update May 24, 2024 at 12:22 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOTEST AG |
| Issuer | Morgan Stanley |
| WKN | MG1LDL |
| ISIN | DE000MG1LDL3 |
| Date issued | 2024-04-03 |
| Strike | 13.9 € |
| Maturity | Unlimited |
| Parity | 1.32 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.59 € |
|---|---|
| Lowest since issue | 10.04 € |
Company Profile
Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. It develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.
Sector
-
Consensus: Biotest AG
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
27.6
EUR
Average target price
37
EUR
Spread / Average Target
+34.06%
- Stock Market
- Certificates
- Certificat
